Ratings Coloplast A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 14:34:25 12/09/2024 BST			5-day change	1st Jan Change
923.80 ^DKK	-0.24%		+3.44%	+20.00%

08-26	COLOPLAST : Q3 24: Chronic care momentum makes up for urology pain
08-21	Jyske Bank Downgrades Coloplast to Hold, Trims PT	MT

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 40.75 and 34.75 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Over the past twelve months, analysts' opinions have been revised negatively.

Source: Surperformance

Source: Refinitiv

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
COLOPLAST A/S		30.73B
INTCO MEDICAL TECHNOLOGY CO., LTD.	-	2.53B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED		2.53B
WINNER MEDICAL CO., LTD.		2.04B
HARTALEGA HOLDINGS		1.88B
TOP GLOVE CORPORATION BHD.		1.66B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-	1.59B
NAKANISHI INC.		1.47B
GVS S.P.A.		1.22B
KOSSAN RUBBER INDUSTRIES		1.07B
Average		4.67B
Weighted average by Cap.